Farxiga approved in the US to reduce the risk of hospitalisationfor heart failure in patients with type-2 diabetes
21 October 2019 07:00 BST Farxiga approved in the US to reduce the risk of hospitalisationfor heart failure in patients with type-2 diabetes AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The approval is based on results from the landmark DECLARE-TIMI 58 CV outcomes trial (CVOT), the largest sodium-glucose cotransporter 2 (SGLT2)